Diffusion Pharmaceuticals Regains Compliance with Nasdaq Capital Market Minimum Equity Rule
November 20, 2017 08:00 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq:DFFN) (“Diffusion” or “the Company”), is a clinical-stage biotechnology company focused on extending...
Diffusion Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
November 13, 2017 08:00 ET
|
Diffusion Pharmaceuticals Inc.
FDA Clears Phase 3 Protocol for Patient Enrollment in GBM Brain Cancer Trial“First Patient In” Expected this YearCompany Charter Amendment Addresses Nasdaq Listing IssueAdditions to Board and...
Diffusion Pharmaceuticals Receives Final FDA Protocol Guidance for Phase 3 Clinical Trial with TSC in Patients Newly Diagnosed with Inoperable Glioblastoma Multiforme
October 17, 2017 07:30 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the...
Diffusion Pharmaceuticals to Present at the 2017 BIO Investor Forum
October 10, 2017 10:00 ET
|
Diffusion Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on the development...
Diffusion Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
September 05, 2017 11:10 ET
|
Diffusion Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on the...
Diffusion Pharmaceuticals Names William Hornung Chief Business Officer
August 23, 2017 07:30 ET
|
Diffusion Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on the development...
Diffusion Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
August 14, 2017 16:01 ET
|
Diffusion Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on the development...
Diffusion Pharmaceuticals Selects Contract Research Organization for Phase 3 Clinical Trial of Lead Compound TSC for Inoperable GBM Brain Cancer
July 31, 2017 08:30 ET
|
Diffusion Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., July 31, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN), a clinical stage biotechnology company developing novel small molecule therapeutics for cancer...
Diffusion Pharmaceuticals Achieves Drug Production Milestone For Planned Phase 3 Clinical Trial In Inoperable GBM Brain Cancer
July 20, 2017 08:30 ET
|
Diffusion Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., July 20, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a clinical stage biotechnology company developing novel small molecule therapeutics for cancer...
Diffusion Pharmaceuticals Appoints Dr. Robert Ruffolo to Board of Directors
July 06, 2017 08:00 ET
|
Diffusion Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., July 06, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a clinical stage biotechnology company focused on the development of novel small molecule...